4-amino-1-[(2R,3S,4S,5R)-5-ethyl-3,4-dihydroxyoxolan-2-yl]pyrimidin-2-one

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: 4-amino-1-[(2R,3S,4S,5R)-5-ethyl-3,4-dihydroxyoxolan-2-yl]pyrimidin-2-one
• 化学式: C₁₀H₁₅N₃O₄
• 分子量: 241.24
• InChiKey: OBQUYPMEXBMPLF-BUJSFMDZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• SUBSTITUTED NUCLEOTIDE ANALOGS
  申请人：Beigelman Leonid

  公开号：US20120070411A1

  公开（公告）日：2012-03-22

  Disclosed herein are phosphoroamidate nucleotide analogs, methods of synthesizing phosphoroamidate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphoroamidate nucleotide analogs.

  本文揭示了磷酰胺核苷类似物、合成磷酰胺核苷类似物的方法以及使用磷酰胺核苷类似物治疗病毒感染、癌症和/或寄生虫病等疾病和/或病况的方法。
• FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING
  申请人：Ramachandra Sumant

  公开号：US20110097340A1

  公开（公告）日：2011-04-28

  Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
• US8216571B2
  申请人：——

  公开号：US8216571B2

  公开（公告）日：2012-07-10
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DU CANCER
  申请人：MOHAN M ALAPATI

  公开号：WO2016203352A2

  公开（公告）日：2016-12-22

  The compositions and compounds of Formula I, Formula II, Formula III, Formula IV which includes topoisomerase inhibitor molecular conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, delayed release or sustained release, transmucosal, syrup, intravenous, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, nanoparticle, buccal administration or transdermal administration. Such compositions may be used to treatment of metastasis, neoplasms, metastatic carcinoma of the colon or rectum, metastatic breast cancer, platinum-resistant ovarian cancer, bevacizumab (avastin)-refractory high-grade glioma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), GI and solid tumors.